| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 5967 | 2015 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4005 | 2018 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1253 | 2015 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1036 | 2016 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1031 | 2013 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 894 | 2019 |
| Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ... New england journal of medicine 375 (23), 2246-2254, 2016 | 790 | 2016 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 707 | 2019 |
| Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma HK Jensen, F Donskov, N Marcussen, M Nordsmark, F Lundbeck, ... J Clin Oncol 27 (28), 4709-4717, 2009 | 515 | 2009 |
| Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ... European urology 66 (4), 704-710, 2014 | 497 | 2014 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ... ESMO open 5 (6), e001079, 2020 | 451 | 2020 |
| Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma RJ Motzer, NB Haas, F Donskov, M Gross-Goupil, S Varlamov, ... Journal of Clinical Oncology 35 (35), 3916, 2017 | 376 | 2017 |
| The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first … JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ... The lancet oncology 16 (3), 293-300, 2015 | 367 | 2015 |
| Belzutifan for renal cell carcinoma in von Hippel–Lindau disease E Jonasch, F Donskov, O Iliopoulos, WK Rathmell, VK Narayan, ... New England Journal of Medicine 385 (22), 2036-2046, 2021 | 365 | 2021 |
| Impact of immune parameters on long-term survival in metastatic renal cell carcinoma F Donskov, H von der Maase J Clin Oncol 24 (13), 1997-2005, 2006 | 357 | 2006 |
| Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis M Shen, P Hu, F Donskov, G Wang, Q Liu, J Du PloS one 9 (6), e98259, 2014 | 348 | 2014 |
| Immunomonitoring and prognostic relevance of neutrophils in clinical trials F Donskov Seminars in cancer biology 23 (3), 200-207, 2013 | 316 | 2013 |
| Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma TO Jensen, H Schmidt, HJ Møller, F Donskov, M Høyer, P Sjoegren, ... Cancer 118 (9), 2476-2485, 2012 | 303 | 2012 |
| Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy RR McKay, N Kroeger, W Xie, JL Lee, JJ Knox, GA Bjarnason, ... European urology 65 (3), 577-584, 2014 | 251 | 2014 |
| CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma B Escudier, P Sharma, DF McDermott, S George, HJ Hammers, S Srinivas, ... European urology 72 (6), 962-971, 2017 | 247 | 2017 |
